Peel Hunt Reaffirms Buy Rating for Sinclair Pharma PLC (SPH)
Peel Hunt reissued their buy rating on shares of Sinclair Pharma PLC (LON:SPH) in a research report released on Tuesday morning, StockTargetPrices.com reports. The firm currently has a GBX 68 ($0.89) price objective on the specialty pharmaceutical company’s stock.
Other analysts have also recently issued reports about the company. Stifel Nicolaus increased their price target on Sinclair Pharma PLC from GBX 49 ($0.64) to GBX 63 ($0.82) and gave the stock a buy rating in a research report on Wednesday, September 14th. Jefferies Group dropped their price target on Sinclair Pharma PLC from GBX 60 ($0.78) to GBX 55 ($0.72) and set a buy rating on the stock in a research report on Wednesday, June 15th. N+1 Singer reiterated a buy rating on shares of Sinclair Pharma PLC in a research report on Wednesday, September 21st. Finally, Royal Bank Of Canada reiterated an outperform rating on shares of Sinclair Pharma PLC in a research report on Thursday, September 15th. Five research analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and an average price target of GBX 57 ($0.74).
Shares of Sinclair Pharma PLC (LON:SPH) opened at 28.75 on Tuesday. The stock’s market capitalization is GBX 142.88 million. Sinclair Pharma PLC has a 12 month low of GBX 26.00 and a 12 month high of GBX 61.33. The stock has a 50 day moving average price of GBX 29.11 and a 200 day moving average price of GBX 32.18.
About Sinclair Pharma PLC
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.